SEATTLE, June 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Needham 7th Annual Biotechnoloy and Medical Technology Conference in New York City, on Wednesday, June 11, 2008 at 9:30 a.m. ET.
A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com/. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. DATASOURCE: Dendreon Corporation CONTACT: Jennifer Cook Williams, Investor Relations of Dendreon Corporation, +1-206-829-1500 Web site: http://www.dendreon.com/
|